The Bombay High Court urged the Maharashtra FDA to act judiciously concerning Cadila Pharmaceuticals’ medicine ban. The court questioned the regulator’s drastic actions before conducting proper inquiries. The FDA agreed to revoke orders and provide Cadila an opportunity to be heard. Cadila had already suffered substantial losses due to the sale ban. The court emphasized the impact of medicine unavailability on patients.